1. 至少1/2的人过早地死亡，都是死于潜在的可预防性的疾病，而且超过1/2的人，其Hcy水平都高。

 

 

2. 根据WHO的预测，全球每年有1670万人死于心血管疾病。高水平的Hcy，对于发生心脏病的风险性增加了50%。

 

 

3. 全球，每年有3200万人发生心脏病和中风，其中1250万导致死亡。由于中风而引起死亡的人群中，40%与高水平的Hcy相关。

 

 

4. 全球，接近1800万人患痴呆，其中阿茨海默病占55%。Hcy水平高于14µmol/L，发生阿茨海默病的风险性增大150%。

 

 

降低风险：

 

 

Hcy水平下降3µmol/L，发生心脏病的可能性下降了16%，中风下降了24%，深静脉血栓下降了25%。

 

 

Hcy水平下降5µmol/L，所有原因导致死亡的风险性下降了49%，心血管疾病导致的死亡下降了50%，癌症导致的死亡下降了26%。

 

 

参考文献：

 

1) Alzheimer’s Society UK (2005), Policy Positions – Demography

 

2) American Heart Association (2004), International Cardiovascular Disease Statistics fact sheet

 

3) American Heart Association (2004), Heart and stroke facts

 

4) American Heart Association (2005), Homocysteine, Folic Acid and Cardiovascular Disease

 

5) Borjel AK, Nilsson TK, Hurtig-Wenloff A, Yngve A, Sjostrom M “Plasma Homocysteine levels, MTHFR polymorphisms 677C>T, 1298A>C, 1793G>A, and school achievement in a population sample of Swedish Children. Haematologica Reports Vol 1 (3) June 2005; Communication C004, page 4. Homocysteine Metabolism 5th International Conference June26-30, 2005.)

 

6) Bostom AG et al. (1999) Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. Ann Intern Med, 131(5).

 

7) Delle Chiaie R, Pancheri P. and Scapicchio P. (2002) Efficacy and tolerability of oral and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. Am J Clin Nutr., 76(5).

 

8) Elias, M. (2005) 4th Conference on Hyperhomocysteinemia, Saarbruecken, Germany. Presentation - Age, Cognition and Homocysteine: News from Framingham.

 

9) Gerritsen T et al. (1962) The identification of homocysteine in the urine. Biochem Biophys Res Comm, 175.

 

10) Hoogeveen EK et al. (2000) Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn Study. Circulation, 101(13).

 

11) Lieber CS. (2002) S-adenosyl-L-methionine: its role in the treatment of liver disorders. Am J Clin Nutr., 76(5).

 

12) Mroczek, WJ, Lee, WR, and Davidov, ME. (1997) Effect of magnesium sulphate on cardiovascular hemodynamics. Angiology, 28(10).

 

13) Nelen WL et al. (2000) Homocysteine and folate levels as risk factors for recurrent early pregnancy loss. Obstet. Gynecol., 95(4).

 

14) Soeken KL et al. (2002) Safety and efficacy of S-adenosylmethionine (SAMe) for osteoarthritis. Journal of Family Practice, 51.

 

15) Vollset SE et al. (2000) Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes; the Hordaland Homocysteine study. Am J Clin Nutr, 71(4).

 

16) Vollset SE, Refsum H, Tverdal A, Nygard O, Nordrehaug JE, Tell GS, Ueland PM. Plasma total homocysteine and cardiovascular and noncardiovascular mortality: the Hordaland Homocysteine Study. Am J Clin Nutr. 2001 Jul;74(1):130-6.

 

17) Wald DS, Law M, Morris JK. (2002) Homocysteine and cardiovascular disease; evidence on causality from a meta-analysis. BMJ, 325(7374).

 

18) Yang, Q. (2005) 4th Conference on Hyperhomocysteinemia, Saarbruecken, Germany. Presentation – Folic Acid Fortification in North America: Mortality by Stroke and Cardiac Arrest sinks

 

19) Yoshihiro Sato et al. (2005) Effect of Folate and Mecobalamin on Hip Fractures in Patients With Stroke. JAMA, 293.